NASDAQ$STRO
Sutro Biopharma Inc · Q1 2021 earnings
Q1 2021 earnings · · Investor relations
Briefing
Sutro Biopharma reported financial results for the first quarter of 2021 and provided business highlights.
Sutro Biopharma reported revenue of $14.7 million for the quarter ended March 31, 2021, and cash, cash equivalents and marketable securities of $294.9 million as of March 31, 2021. The company anticipates that the cash runway will last into the second half of 2023.
- Follow-up data on STRO-002 from the Phase 1 dose-escalation will be presented at ASCO 2021.
- Merck initiated IND-enabling toxicology studies for the first program under the cytokine derivatives collaboration resulting in a $15 million milestone payment earned in April 2021.
- EMD Serono began a Phase 1 study for the bispecific MUC1-EGFR ADC, M1231, during the first quarter of 2021.
- Financial position remains strong with cash, cash equivalents and marketable securities of $294.9 million as of March 31, 2021 and projected runway into the second half of 2023
Headline financials
Revenue & EPS history
Sutro · Revenue · Quarterly
$14.7M
Revenue by segment
Sutro · $14.5M total across 2 segments · Q1 2026
- Astellas Pharma Inc.$14.5M—99.9%
- Vaxcyte, Inc.$15K—0.1%
Forward guidance
Sutro anticipates continued progress in clinical trials and advancement of product candidates.
Tailwinds
- Ongoing enrollment in dose-expansion trial for patients with advanced ovarian cancer
- Initial data for dose-expansion is expected to be reported in the second half of 2021
- Continuing enrollment in Phase 1 dose-escalation for patients with B-cell malignancies
- Product candidate STRO-003 expected to be unveiled in the second half of 2021
- Moving towards the clinic on the first cytokine derivatives program for cancer and autoimmune disorders
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q1 2021
-0.8%
Avg return
Earnings day
-0.7%
Avg return
5 days after
+6.4%
Avg return
30 days after
42%
13 / 31 earnings
Positive
+22.2%
Q4 2023
Best reaction
-29.4%
Q4 2019
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -3.1% | -20.2% | — | |
| Q4 2025 | +2.8% | +14.5% | +63.3% | |
| Q3 2025 | -15.8% | -13.8% | -7.9% | |
| Q2 2025 | -2.1% | -4.9% | +29.3% | |
| Q1 2025 | -3.8% | -1.1% | -3.3% | |
| Q4 2024 | -11.7% | -20.3% | +21.6% | |
| Q3 2024 | -15.4% | -32.6% | -48.0% | |
| Q2 2024 | +10.8% | +29.9% | +37.3% | |
| Q1 2024 | +4.6% | -3.4% | -6.0% | |
| Q4 2023 | +22.2% | +65.2% | +1.5% | |
| Q3 2023 | +13.9% | +29.3% | +88.9% | |
| Q2 2023 | +0.9% | +1.2% | +7.1% | |
| Q1 2023 | +1.6% | -4.1% | -5.3% | |
| Q4 2022 | -3.1% | -9.6% | -10.7% | |
| Q3 2022 | -2.5% | -3.7% | +4.6% | |
| Q2 2022 | +14.6% | +23.1% | -2.4% | |
| Q1 2022 | -6.8% | -19.6% | -19.2% | |
| Q4 2021 | -2.5% | -8.0% | -8.3% | |
| Q3 2021 | -5.3% | -11.3% | -32.2% | |
| Q2 2021 | -0.2% | +2.3% | +12.4% | |
| Q1 2021 | +8.3% | +9.7% | -0.5% | |
| Q4 2020 | +4.2% | -3.7% | -16.5% | |
| Q3 2020 | +17.8% | +12.4% | +62.7% | |
| Q2 2020 | +1.7% | +1.0% | +48.9% | |
| Q1 2020 | -9.8% | -8.1% | +0.4% | |
| Q4 2019 | -29.4% | -19.9% | -3.4% | |
| Q3 2019 | -1.1% | -1.2% | -7.5% | |
| Q2 2019 | -7.0% | -3.8% | +19.6% | |
| Q1 2019 | -7.6% | -7.9% | +1.8% | |
| Q4 2018 | +5.4% | -1.2% | -12.6% | |
| Q3 2018 | -5.0% | -13.1% | -23.2% | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — | |
| Q4 2017 | — | — | — | |
| Q3 2017 | — | — | — | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro